Marques, JoanaValle-Delgado, Juan JoséUrbán, PatriciaBaró, ElisabetProhens, RafelMayor, AlfredoCisteró, PauDelves, MichaelSinden, Robert E.Grandfils, Christiande Paz, José L.García-Salcedo, José A.Fernàndez-Busquets, Xavier2018-05-242018-05-242017-02-011549-9634PURE: 3281908PURE UUID: d102000b-f41d-4003-8e65-a55be04a880aScopus: 85009876187PubMed: 27720930ORCID: /0000-0003-1827-2912/work/68960819http://www.scopus.com/inward/record.url?scp=85009876187&partnerID=8YFLogxKThe adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.111296147engGlycosaminoglycansMalariaNanomedicinePlasmodiumTargeted drug deliveryBioengineeringMedicine (miscellaneous)Molecular MedicineBiomedical EngineeringGeneral Materials SciencePharmaceutical ScienceSDG 3 - Good Health and Well-beingjournal article10.1016/j.nano.2016.09.010https://www.scopus.com/pages/publications/85009876187